Amarantus Bioscience Holdings Inc., of San Francisco, said the FDA granted the company's investigational drug MANF (mesencephalic-astrocyte-derived neurotrophic factor) orphan drug designation for the treatment of retinitis pigmentosa (RP), a group of inherited diseases causing retinal degeneration often leading to blindness.